No Data
No Data
三葉草生物-B:2023年度報告
Selected announcements | China's non-ferrous mining industry plans to sell up to 163 million shares at a discount of about 13.54%; Longyuan Electric Power's power generation will increase by about 10% during the year
China's net profit for the first quarter was 2,308 billion yuan, up 0.33% year on year; Qiutai Technology sold about 368.39 million mobile phone camera modules in March, up 31.8% from month to month, down 1.7% year on year.
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial
Clover Biopharmaceuticals (HKG:2197) announced positive preliminary results from the Phase 1 clinical trial of its SCB-1019 vaccine candidate for respiratory syncytial virus (RSV) in Australia, accord
Clover Bio-B (02197.HK) Announces Bivalent RSV Vaccine Candidate SCB-1019 Phase I Clinical Trial Receives Positive Preliminary Data
Gelonghui, April 8, 丨 Clover Bio-B (02197.HK) announced that in the phase I clinical trial of the bivalent RSV PreF-trimer subunit vaccine candidate SCB-1019 developed by the evaluation company based on Clover Biotech's unique Trimer-Tag (protein trimerization) vaccine technology platform, the first batch of young adults obtained positive preliminary immunogenicity and safety data. In the phase I clinical trial, the first group of young adults (ages 18-59) received SCB-1019 or saline placebo on day 0 (before vaccination) and day 28 (vaccination), respectively
Clover Bio-B (02197.HK) grants 9.463 million share options and 7.205 million restricted share units
Glonghui, April 2, 丨 Clover Bio-B (02197.HK) announced that on April 2, 2024, (i) the company granted a total of 9.463 million share options and 7.205 million restricted share units to certain eligible participants in accordance with the terms of the initial public offering after-sales share option plan and the restricted share unit plan, respectively; and (ii) the restricted share unit scheme will only be funded by existing shares and will not be funded by any new shares.
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
No Data